Are you curious about drug discovery ? Do you have questions about recent evolutions ? You should look at this course from Coursera. It will give you the major aspects of the drug discovery process and an overview of this changing landscape.

The University of California San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences Drug Discovery course brings you lectures from both faculty and industry experts. With this course, recorded on campus at UCSD, we seek to share our access to top people in the field who bring an unprecedented range of expertise on drug discovery.

Source: Drug Discovery | Coursera

This year again, we are very happy to participate in France Digital #StartupAssembly. This national action aims to help people to discover what is innovation “on the field” ! Over 1000 startups are open and France Digital waits for almost 10000 people.


If you want to meet us in Rennes november 15 ou november 16, you will be welcome ! Registration is avalaible on these links : november 15 / november 16

As last year, we were present in Biofit. This congress is one of the best european place to be for B2B meetings. I had around 20 B to B meetings to discuss partnering and business, with biotech companies, other CROs and with public transfert technology societies as SATT in France or ErasmusMC in The Netherlands. That I can observe is that B2B meetings with pharmaceutical industries are increasingly turned to partnering around drugs already in clinical development rather than business around innovative projects. Nevertheless, it was a good place to discuss partnering with others CROs and biotech companies.

Do you know what is phenotypic screening ? If you are here I think yes 🙂 But if you want to explain it easily, I strongly recommend the reading of Perkin Elmer white paper « Phenotypic Drug Discovery with High Content Screening ». It’s short (only 4 pages) but it contents main information to understand differences between « target based » and « phenotypic screening » approaches in drug discovery.

It explains also the importance of the technology side and the digital side of HCS and finally, give a good summarize of our vision :

“Today’s drug discovery strategies require candidate compounds to fail early and cheaply in the discovery stage, rather than late and expensively in the clinical phase. Testing compounds from the beginning in physiologically relevant model systems and leveraging the rich information available in image-based screens are ways to focus on those compounds that give rise to the right phenotypic changes without undesirable effects on the system. High Content Screening with highly detailed multiparametric assays in conjunction with modern machine-learning tools provide a promising way to achieve this goal.”

 Source :

We will be present in the “innovation zone” during the Drug discovery 2015 in Telford the 2nd and 3rd of September. The event is organised by ELRIG into 8 scientific sessions, which one is on phenotypic discovery and cell imaging. For participants, this event is free of charge. Thus, come and see us in the innovation zone!
If you want more detail about this event, follow this link:

%d bloggers like this: